🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Identification of an Immune Single Cell Transcriptomic Profile of Responder and Non-responder Hepatocellular Carcinoma Patients Treated With Immune-checkpoint Inhibitors

Recruitingn/aAges 18 Years - 90 YearsAllFondazione IRCCS Policlinico San Matteo di Pavia
NCT07273708 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The study aims to analyze blood samples from patients with advanced hepatocellular carcinoma who are receiving systemic treatment with immunotherapy. The objective is to determine whether treatment exposure leads to changes in the transcriptomic patterns of peripheral blood mononuclear cells (PBMCs), if these changes are associated with treatment response, and whether certain pre-treatment transcriptomic signatures can predict response to treatment. As an exploratory objective, PBMCs derived from patients exposed to immune checkpoint inhibitors will be co-cultured with their paired tumor cells in organoid cultures. This aims to assess whether these preclinical 3D models correlate with clinical outcomes.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. diagnosis of advanced HCC treated with atezolizumab plus bevacizumab or tremelimumab single dose plus durvalumab (STRIDE regimen) as first-line treament 2. age ≥18 and \<90 years at time of signing informed consent 3. Signed Informed Consent Form Exclusion Criteria: 1. Life expectancy of \<12 months due to concomitant diseases 2. Active or history of autoimmune disease or immune deficiency on inflammatory chronic diseases 3. Ongoing drug abuse 4. History of malignancy other than HCC within 3 years prior to study entry with the following exception: 1. Completely resected malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate 90%) and without evidence of recurrence for \> 3 years prior to study entry 2. adequately treated non-melanoma skin carcinoma or lentigo maligna without evidence of metastases. 3. adequately treated carcinoma in situ of the cervix without evidence of recurrence 4. localised prostate cancer 5. adequately treated non invasive or in situ urothelial cancers 5. evidence or history of positive HIV test 6. inability to comply with the study protocol, in the investigator's judgment
💊

What it tests

  • Not listed
📍

Where

1 site
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy